secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001823239-22-000015
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q1 revenue $244.3M (+65% YoY); net income $146.9M; raises FY22 guidance
-------------------------------------------------------------------------------

- Record Q1 revenue $244.3M, up 65% YoY; Nucleic Acid Production $223.7M (+80%).
- Net income $146.9M (+95% YoY); Adjusted EBITDA $187.0M (77% margin).
- Nucleic Acid Production base business (ex-COVID CleanCap) revenue grew 55% YoY.
- Full-year 2022 revenue guidance reaffirmed; Adjusted EBITDA and EPS guidance raised.
- Deborah Barbara appointed Vice President, Business Development and Strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323922000015/0001823239-22-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323922000015/mrvi-20220505.htm
  HTML page:      https://secwatch.observer/filing/0001823239-22-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer